Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
Latest Information Update: 07 Dec 2024
At a glance
- Drugs Ciltacabtagene autoleucel (Primary)
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- Sponsors Janssen
Most Recent Events
- 29 Apr 2022 New trial record